Dr. Roee Atlas is the CEO of Rambam MedTech, the Technology Transfer company of Rambam. Prior to the current position, Roee led a Pharma/biopharma Incubator (The NIBN), at Ben Gurion University. The Incubator focused on pre-clinical development of pharmaceutical and biopharmaceutical drug entities, for indications such as cancer, autoimmunity, neurodegeneration, metabolism, and more. At this position Roee moved forward pre-clinical development programs for small molecules, peptides, and biopharmaceuticals. In addition to technology development, Roee led the intellectual property field, and the business and commercialization aspects of the Incubator. Prior to that Roee served as CEO of a small biotech startup company centered on pain management in dentistry application. Before that Roee held a position of a project manager at Omrix Biopharmaceuticals (a Johnson and Johnson company), in charge of pre-clinical development of regenerative medicine and tissue engineering applications for Fibrin polymer technology.
Roee studied molecular biology and completed a PhD degree at Weizmann Institute in 2005, followed by a postdoc fellowship at Columbia Medical school, New York.